Prophylactic Protection Against Respiratory Viruses Conferred by a Prototype Live Attenuated Influenza Virus Vaccine.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an immediate antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.
Identifiants
pubmed: 34401874
doi: 10.21203/rs.3.rs-668116/v1
pmc: PMC8366806
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI141226
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145870
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI097092
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Genes Dev. 1998 Jul 1;12(13):2061-72
pubmed: 9649509
Nat Biotechnol. 1999 Jun;17(6):583-7
pubmed: 10385324
Cell Host Microbe. 2009 May 8;5(5):439-49
pubmed: 19454348
Cell. 1986 Jan 17;44(1):147-58
pubmed: 3000619
EMBO J. 1994 Feb 1;13(3):704-12
pubmed: 8313914
Vaccine. 2013 Dec 16;31(52):6194-200
pubmed: 24183981
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
J Virol. 1990 Jul;64(7):3370-5
pubmed: 2161946
J Virol. 2000 Sep;74(17):7989-96
pubmed: 10933707
Mol Cell. 1998 Jun;1(7):991-1000
pubmed: 9651582
Rev Med Interne. 2002 Nov;23 Suppl 4:449s-458s
pubmed: 12481400
PLoS One. 2009 Jun 19;4(6):e5984
pubmed: 19543385
Vaccine. 2009 May 11;27(21):2851-7
pubmed: 19366569
J Virol. 2013 Feb;87(3):1290-300
pubmed: 23175362
J Virol. 1992 Apr;66(4):2564-9
pubmed: 1548781
Virology. 2018 Feb;515:150-157
pubmed: 29288958
Emerg Microbes Infect. 2020 Dec;9(1):2433-2445
pubmed: 33073694
Int Rev Immunol. 2002 Jul-Oct;21(4-5):305-37
pubmed: 12486817
Cell Rep. 2016 Feb 23;14(7):1632-1640
pubmed: 26876165
Virology. 2006 May 25;349(1):13-21
pubmed: 16466763
Zool Res. 2017 May 18;38(3):146-154
pubmed: 28585438
Adv Virus Res. 2018;100:355-378
pubmed: 29551142
Mol Ther. 2017 Sep 6;25(9):2093-2103
pubmed: 28760668
Vaccine. 1999 Mar 26;17(13-14):1788-95
pubmed: 10194841
J Virol. 2000 Jul;74(13):6203-6
pubmed: 10846107
J Hepatol. 2000 Dec;33(6):998-1002
pubmed: 11131465
J Clin Endocrinol Metab. 1996 Sep;81(9):3265-9
pubmed: 8784081
J Virol. 2007 Jan;81(2):514-24
pubmed: 17079289
Vaccine. 2019 Jun 19;37(28):3722-3729
pubmed: 31155415
J Virol. 2015 Nov;89(21):10879-90
pubmed: 26292322
Mol Cell Biol. 1988 Oct;8(10):4518-23
pubmed: 2903437
J Virol. 1994 Apr;68(4):2425-32
pubmed: 7908060
Memo. 2016;9:63-65
pubmed: 27429657
Vaccine. 2007 Nov 19;25(47):7999-8009
pubmed: 17933442
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
Proc Natl Acad Sci U S A. 1983 Apr;80(7):1910-4
pubmed: 6188159
J Immunol. 1999 Apr 1;162(7):4184-90
pubmed: 10201945
J Virol. 2000 Dec;74(24):11566-73
pubmed: 11090154
Nat Immunol. 2016 May;17(5):523-30
pubmed: 26998762
J Virol. 2006 Nov;80(22):11009-18
pubmed: 16943300
Nat Commun. 2018 May 8;9(1):1820
pubmed: 29739942
J Virol. 2016 Apr 14;90(9):4696-4705
pubmed: 26912617
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7100-5
pubmed: 16627618
J Virol. 2010 Feb;84(4):1847-55
pubmed: 19939929
Virology. 1998 Dec 20;252(2):324-30
pubmed: 9878611
Cell Host Microbe. 2017 Aug 9;22(2):176-184
pubmed: 28799903
Nature. 1980 Feb 14;283(5748):660-2
pubmed: 7354853
Curr Opin Immunol. 2016 Feb;38:109-20
pubmed: 26761402
Proc Natl Acad Sci U S A. 1967 Aug;58(2):782-9
pubmed: 5233474
Cancer Res. 1998 Jun 15;58(12):2489-99
pubmed: 9635566
J Virol. 2013 Jun;87(12):6660-7
pubmed: 23552410
Immunity. 2006 Sep;25(3):343-8
pubmed: 16979566
J Immunol. 2018 Dec 15;201(12):3479-3485
pubmed: 30530500
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10818-23
pubmed: 10485909
Future Microbiol. 2010 Jan;5(1):23-41
pubmed: 20020828
J Immunol Methods. 1999 Jan 1;222(1-2):189-96
pubmed: 10022385
J Infect Dis. 1970 Jun;121(6):615-23
pubmed: 4316147
J Virol. 1998 Aug;72(8):6283-90
pubmed: 9658066
N Engl J Med. 1989 Nov 30;321(22):1506-10
pubmed: 2509917
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28344-28354
pubmed: 33097660
Vaccine. 2014 Apr 7;32(17):1897-900
pubmed: 24560674
Semin Oncol. 1998 Feb;25(1 Suppl 1):39-47
pubmed: 9482539
J Interferon Res. 1989 Oct;9(5):583-90
pubmed: 2794581
Infect Immun. 1983 Feb;39(2):879-88
pubmed: 6299951
BMC Biol. 2012 May 24;10:44
pubmed: 22626058
J Natl Cancer Inst. 2010 Apr 7;102(7):493-501
pubmed: 20179267
Virology. 1999 Mar 30;256(1):85-91
pubmed: 10087229
Curr Opin Virol. 2015 Jun;12:1-6
pubmed: 25638592
J Gen Virol. 2009 Dec;90(Pt 12):2990-2994
pubmed: 19726611
J Gen Virol. 2000 Mar;81(Pt 3):737-42
pubmed: 10675411
Nat Struct Mol Biol. 2010 May;17(5):530-8
pubmed: 20383144
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
Pharm World Sci. 2005 Dec;27(6):423-31
pubmed: 16341948